SCHEMBL30706740

SCHEMBL30706740

CC1(C)OB(c2c(C3CC3)c(Cl)cc3c2cnn3COCC[Si](C)(C)C)OC1(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30707404 0.89 — —
SCHEMBL32660937 0.85 UCHL1 (0.30) —
SCHEMBL26695189 0.81 UCHL1 (0.30) —
SCHEMBL30707514 0.81 DGAT1 (0.31) —
SCHEMBL30706688 0.81 PTGER3 (0.32) —
SCHEMBL25368395 0.75 DGAT1 (0.33) —
SCHEMBL29493773 0.75 DGAT1 (0.33) —
SCHEMBL30706713 0.73 DGAT1 (0.30) —
SCHEMBL31219977 0.73 UCHL1 (0.35) —
SCHEMBL31127775 0.72 RXRA (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 — — US disclosed
EP-4540255-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244615-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed
Send feedback